The purpose of this study was to retrospectively evaluate the incidence of distant metastasis (DM) after curative surgical treatment and assess the multivariate relationships among various risk factors for DM in patients with oral squamous cell carcinoma (OSCC).
Study Design
Case series with chart review.
Setting
Tertiary referral center.
Subjects and Methods
The medical records of all patients with OSCC without DM who underwent curative surgery with or without postoperative adjuvant chemoradiation between January 2001 and February 2014 at our institution were retrospectively reviewed. There were a total of 451 patients, including 271 men and 180 women, with a mean age of 65.9 ± 13.5 years.
Results
Of these patients, 30 (6.7%) developed DM. During the follow-up period, the 5-year overall survival rate was 76.2%. Sites of DM comprised the lungs (80.0%), skin (13.3%), liver (10.0%), bone (6.7%), and brain (3.3%). We found the T classification and N classification as well as the histologic grade to be significant risk factors associated with the development of DM in the univariate analysis only (P = .003), whereas locoregional failure (odds ratio [OR], 4.03), multiple lymph node metastases (more than 4 positive nodes; OR, 3.32) and positive extracapsular spread (OR, 3.06) were identified to be significant risk factors associated with the development of DM in the multivariate analysis.
Conclusion
We demonstrated multivariate relationships among various risk factors for DM in OSCC patients. Clinicians should consider these risk factors and pay special attention to detecting DM early during the postoperative management of OSCC patients with these risk factors.
RoseBSJeongJHNathSKLuSMMellLK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011;29:3503-3509.
2.
LiaoCTChangJTWangHM. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915-922.
3.
LiaoCTWangHMChangJT. Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer. 2007;110:1501-1508.
4.
HongWKBromerRHAmatoDA. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer. 1985;56:1242-1245.
5.
LeónXQuerMOrúsCdel Prado VenegasMLópezM. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck. 2000;22:680-686.
6.
FerlitoAShahaARSilverCERinaldoAMondinV. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202-207.
7.
GaravelloWCiardoASpreaficoRGainiRM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:762-766.
8.
LiXDiBShangYZhouYChengJHeZ. Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas. Eur J Surg Oncol. 2009;35:1348-1353.
9.
CalhounKHFulmerPWeissRHokansonJA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1199-1205.
10.
TroellRJTerrisDJ. Detection of metastases from head and neck cancers. Laryngoscope. 199;105:247-250.
11.
LimYCKooBSChoiEC. Bilateral neck node metastasis: a predictor of isolated distant metastasis in patients with oral and oropharyngeal squamous cell carcinoma after primary curative surgery. Laryngoscope. 2007;117:1576-1580.
12.
ShingakiSSuzukiIKobayashiTNakajimaT. Predicting factors for distant metastases in head and neck carcinomas: an analysis of 103 patients with locoregional control. J Oral Maxillofac Surg. 1996;54:853-857.
13.
MyersJNGreenbergJSMoVRobertsD. Extracapsular spread: a significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92:3030-3036.
14.
FortinACoutureCDoucetRAlbertMAllardJTetuB. Does histologic grade have a role in the management of head and neck cancers?J Clin Oncol. 2001;19:4107-4116.
15.
LimJYLimYCKimSHKimJWJeongHMChoiEC. Predictive factors of isolated distant metastasis after primary definitive surgery without systemic treatment for head and neck squamous cell carcinoma. Oral Oncol. 2010;46:504-508.
16.
SumiokaSSawaiNYKishinoMIshihamaKMinamiMOkuraM. Risk factors for distant metastasis in squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg. 2013;71:1291-1297.
17.
ChenTCHsuCWLouPJ. The clinical predictive factors for subsequent distant metastasis in patients with locoregionally advanced oral squamous cell carcinoma. Oral Oncol. 2013;49:367-373.
18.
JerjesWUpileTPetrieA. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2010;2:9.
19.
HuangCGLeeLATsaoKC. Human papillomavirus 16/18 E7 viral loads predict distant metastasis in oral cavity squamous cell carcinoma. J Clin Virol. 2014;61:230-236.
20.
Po Wing YuenALamKYLamLK. Prognostic factors of clinically stage I and II oral tongue carcinoma: a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck. 2002;24:513-520.
21.
O-charoenratPPillaiGPatelS. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol. 2003;39:386-390.
22.
KademaniDBellRBBagheriS. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. 2005;63:1599-1605.
23.
BernierJCooperJSPajakTF. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843-850.
24.
KowalskiLPCarvalhoALMartins PrianteAVMagrinJ. Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 2005;41:534-541.
25.
Liverpool Head and Neck Oncology Group. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5- FU in end stage squamous carcinoma of the head and neck. Br J Cancer. 1990;61:311-315.
26.
JacobsCLymanGVelez-GarcíaE. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257-263.
27.
ForastiereAAMetchBSchullerDE. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol. 1992;10:1245-1251.
28.
GibsonMKLiYMurphyB. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-3567.
29.
ForastiereAALeongTRowinskyE. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group study E1393. J Clin Oncol. 2001;19:1088-1095.
30.
LaramoreGEScottCBal-SarrafM. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705-713.
31.
BachaudJMCohen-JonathanEAlzieuCDavidJMSerranoEDaly-SchveitzerN. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36:999-1004.
32.
SlotmanGJMohitTRainaSSwaminathanAPOhanianMRushBFJr.The incidence of metastases after multimodal therapy for cancer of the head and neck. Cancer. 1984;54:2009-2014.
33.
BaselgaJTrigoJMBourhisJ. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577.
34.
VermorkenJBTrigoJHittR. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177.
35.
ShionoSKawamuraMSatoT. Metastatic Lung Tumor Study Group of Japan. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg. 2009;88:856-860.
36.
MazerTMRobbinsKTMcMurtreyMJByersRM. Resection of pulmonary metastases from squamous carcinoma of the head and neck. Am J Surg. 1988;156:238-242.
37.
WedmanJBalmAJHartAA. Value of resection of pulmonary metastases in head and neck cancer patients. Head Neck. 1996;18:311-316.
38.
NibuKNakagawaKKamataS. Surgical treatment for pulmonary metastases of squamous cell carcinoma of the head and neck. Am J Otolaryngol. 1997;18:391-395.
39.
FinleyRKIIIVerazinGTDriscollDL. Results of surgical resection of pulmonary metastases of squamous cell carcinoma of the head and neck. Am J Surg. 1992;164:594-598.
